The Company’s headquarters are located at 490 Arsenal Way, Suite 120 in Watertown, MA 02472. The main office number is (617) 231-0700.
C4 Therapeutics stock is traded on the NASDAQ Global Market under the ticker symbol CCCC. The Company’s Initial Public Offering (IPO) was priced on October 1, 2020.
The CUSIP number for the Company’s common stock is 12529R107.
The Company’s fiscal year ends on December 31.
Computershare Trust Company, N.A.
P.O. Box 43006
Providence, RI 02940-3078
www.computershare.com
U.S. Toll Free: +1 800-736-3001
International Phone: +1 781-575-3100
E-mail Inquiries: Web.queries@computershare.com
C4 Therapeutics does not currently have a direct stock purchase plan. The Company’s common stock can be purchased by contacting a securities broker of your choice.
C4 Therapeutics does not currently offer a dividend reinvestment program and does not expect to declare or pay cash or other dividends in our common stock in the foreseeable future.
Legal counsel:
Goodwin Procter LLP
100 Northern Avenue
Boston, MA 02210
(617) 570-1000
Auditor:
KPMG LLP
60 South Street
Boston, MA 02111
(617) 988-1000
To learn more about C4 Therapeutics, please visit our website at www.c4therapeutics.com.
Corporate news can be found in Press Releases section of our Investors webpage.
C4 Therapeutics’ SEC filings can be accessed on the SEC Filings section of our Investors webpage or directly from the SEC at www.sec.gov.
Please contact the C4 Therapeutics’ investor relations team at csolberg@c4therapeutics.com and kendra.adams@c4therapeutics.com with any additional queries.
The date and location of the next annual meeting will be communicated prior to the meeting date.
